Unlock instant, AI-driven research and patent intelligence for your innovation.
Chenodeoxycholic acid derivative or its pharmaceutically acceptable salt, its preparation method and use
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of chenodeoxycholic acid and derivatives, applied in the field of medicinal chemistry
Active Publication Date: 2021-06-11
CHINA PHARM UNIV
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
FXR agonists are mainly divided into steroidal and non-steroidal structures. Currently, there are few drugs on the market, and they are mainly used for the treatment of NASH, biliary cirrhosis, and cholangitis. There are few reports on the research and development of lipid-regulating drugs.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
preparation example Construction
[0032] The synthetic method of partial compound 7 (7a, 7b, 7c, 7d, 7e, 7f, 7g, 7h) of the present invention comprises the following steps:
[0033]
[0034] Reagents and conditions: (a) CH 3 OH; (b)Ac 2 O, DCM; (c) NaOCl, CH 3 COOH, EA; (d) NaOH, HCl; (e) CH 3 OH; (f)NH 2 OH HCl, NaOH, EtOH; (g) LiOH, CH 3 COOH; (h)R-OH, H 2 SO 4 or R-NH, EDCI, HOBt, Et 3 N.
[0035] Some compounds were prepared as follows:
[0036] Melting point was measured by XRC-1 micro melting point apparatus (the thermometer was not calibrated), IR was measured by Nicolet iS10 Fourier transform infrared spectrometer (KBr tablet), 1H-NMR nuclear magnetic resonance was measured by BrukerAV300 (300MHz) nuclear magnetic resonance instrument (TMS is the internal standard), and the mass spectra were determined by Agilem Q-TOF 6520 (HR-MS) and Agilent 1100LC-MSD-Trap / SL mass spectrometer (ESI-MS), respectively.
[0037] The column chromatography silica gel is 100-200 mesh or 200-300 mesh silica gel...
[0040] Cholic acid (5g, 12.2mmol) was dissolved in methanol, and a few drops of H 2 SO 4 , heated to 60°C, and refluxed for 5h. Methanol was removed under reduced pressure to obtain 5 g of crude product, which was directly dropped. Yield: 96.7%. MS m / z[M+H] + = 423.3.
Embodiment 2
[0042] Synthesis of intermediate 3α, 7α-acetoxy-12α-hydroxy-5β-cholanoic acid methyl ester (3)
[0043] Intermediate 2 (crude product 5g, 11.8mmol) was dissolved in DCM, triethylamine (2.6ml), DMAP (75mg, 0.61mmol) were added, acetic anhydride (3.6g, 35.4mmol) was added dropwise, and reacted at room temperature for 3h. Add H 2 O quenched the reaction and stirred for 2h. with DCM and H 2 O extraction, saturated brine dehydration, anhydrous Na 2 SO 4 Dry and spin dry under reduced pressure. Purified by column chromatography, compound 3.3g. Yield: 58.9%. MS m / z[M+H] + = 507.3.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a chenodeoxycholic acid derivative with the structure of general formula I or a pharmaceutically acceptable salt thereof, a preparation method and application thereof, the compound can upregulate the transcription level of FXR mRNA and SHP mRNA, can obviously activate FXR, and can be used It can be used to prepare medicines for treating or preventing hyperlipidemia, atherosclerosis, non-alcoholic steatohepatitis, type II diabetes and other diseases related to blood lipids.
Description
technical field [0001] The invention relates to the technical field of medicinal chemistry, in particular to a chenodeoxycholic acid derivative or a pharmaceutically acceptable salt thereof, a preparation method and application thereof. Background technique [0002] Dyslipidemia is a systemic disease in which one or more lipids in plasma are higher than normal due to abnormal lipid metabolism or operation, which is manifested as high total cholesterol (TC) and / or triglyceride (TG) in blood Or high-density lipoprotein cholesterol (HDL-C) is too low. Dyslipidemia can lead to metabolic diseases such as atherosclerosis, non-alcoholic fatty liver, and type II diabetes. The incidence of cardiovascular disease is closely related to the level of lipoprotein in the body, and the increase of TG, the increase of LDL-C and the decrease of HDL-C are the main risk factors of cardiovascular disease. [0003] Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, is a l...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.